Ida Joanna Korfage
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ida Joanna Korfage has a total of 389 co-authors. Here are the top co-authors by number of shared publications:
- Judith Anna Catharina Rietjens
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
18 shared publications - Agnes van der Heide
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
15 shared publications - Marie-Louise Essink-Bot
Department of Public Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
13 shared publications - Lea J. Jabbarian
Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
8 shared publications Agnes van der Heide
Erasmus Medical Centre, Rotterdam, The Netherlands
7 shared publications- Jan Hendrik Richardus
Affiliation Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
7 shared publications
Latest Publications
- Open Access
- 19 November 2026
- Published by MDPI AG in Health Economics and Policy
- Vol. 1 (2) , 12
Study Protocol for a Cost-Effectiveness Analysis Along a Pre-Test–Post-Test Study Evaluating the Application of Metro Mapping in Clinical Care Paths of Patients with Breast Cancer, Prostate Cancer, and Melanoma in Denmark, The Netherlands, and Spain
Background: Metro Mapping is an innovative service design methodology to co-design clinical care paths to support shared decision-making in oncology. We provide a study protocol for a cost-effectiveness analysis (CEA) evaluating health effects and costs of applying Metro Mapping to redesign selected clinical care paths for patients with cancer. Methods: The CEA will be conducted alongside a pre-test–post-test study evaluating the impact of Metro Mapping on decision-making processes and outcomes in selected clinical care paths of patients with melanoma, breast, or prostate cancer in the Netherlands, Denmark, and Spain. In the pre-test phase, patients follow the standard cancer treatment path. In the post-test phase, patients follow a care path redesigned using Metro Mapping. In the CEA, care after Metro Mapping (i.e., post-test) will be evaluated against care before Metro Mapping (i.e., the pre-test). The CEA adopts a societal perspective; health effects and costs will be evaluated alongside selected care paths in both pre- and post-test groups over a time horizon of 36 months corresponding to the study period. Regret after a healthcare decision based on the decision regret scale (inversely reflecting satisfaction) and health-related quality of life based on EQ-5D-5L and EORTC QLU-C10D will be assessed at the beginning and after six months for each care trajectory, in both groups. Direct medical costs will be estimated using resource utilization from electronic medical records and reimbursement prices. Direct non-medical costs and indirect costs will be assessed through a short version of the iMTA Productivity Cost Questionnaire employed at the end of each care trajectory. Main outcomes are absolute total costs, quality-adjusted life years, decision regret/satisfaction, and the incremental cost-effectiveness ratio for the application of Metro Mapping vs. no Metro Mapping. Health effects and costs will be evaluated using descriptive statistics and multivariable statistical methods to account for baseline confounding. Uncertainty will be assessed through deterministic and probabilistic sensitivity analyses. Discussion: This study protocol describes a prospective and systematic CEA alongside a pre-test–post-test study to evaluate the cost-effectiveness of Metro Mapping in selected care paths of three different cancers and countries, making the research process transparent and reproducible. Trial registration: The pre-test–post-test study has been registered in the clinical.gov trial registry (record number: 8423, identifier: NCT06685562, registration date: 12 November 2024).
- 19 November 2026
- Published by MDPI AG in Health Economics and Policy
- Vol. 1 (2) , 12
Open AccessStudy Protocol for a Cost-Effectiveness Analysis Along a Pre-Test–Post-Test Study Evaluating the Application of Metro Mapping in Clinical Care Paths of Patients with Breast Cancer, Prostate Cancer, and Melanoma in Denmark, The Netherlands, and Spain
Background: Metro Mapping is an innovative service design methodology to co-design clinical care paths to support shared decision-making in oncology. We provide a study protocol for a cost-effectiveness analysis (CEA) evaluating health effects and costs of applying Metro Mapping to redesign selected clinical care paths for patients with cancer. Methods: The CEA will be conducted alongside a pre-test–post-test study evaluating the impact of Metro Mapping on decision-making processes and outcomes in selected clinical care paths of patients with melanoma, breast, or prostate cancer in the Netherlands, Denmark, and Spain. In the pre-test phase, patients follow the standard cancer treatment path. In the post-test phase, patients follow a care path redesigned using Metro Mapping. In the CEA, care after Metro Mapping (i.e., post-test) will be evaluated against care before Metro Mapping (i.e., the pre-test). The CEA adopts a societal perspective; health effects and costs will be evaluated alongside selected care paths in both pre- and post-test groups over a time horizon of 36 months corresponding to the study period. Regret after a healthcare decision based on the decision regret scale (inversely reflecting satisfaction) and health-related quality of life based on EQ-5D-5L and EORTC QLU-C10D will be assessed at the beginning and after six months for each care trajectory, in both groups. Direct medical costs will be estimated using resource utilization from electronic medical records and reimbursement prices. Direct non-medical costs and indirect costs will be assessed through a short version of the iMTA Productivity Cost Questionnaire employed at the end of each care trajectory. Main outcomes are absolute total costs, quality-adjusted life years, decision regret/satisfaction, and the incremental cost-effectiveness ratio for the application of Metro Mapping vs. no Metro Mapping. Health effects and costs will be evaluated using descriptive statistics and multivariable statistical methods to account for baseline confounding. Uncertainty will be assessed through deterministic and probabilistic sensitivity analyses. Discussion: This study protocol describes a prospective and systematic CEA alongside a pre-test–post-test study to evaluate the cost-effectiveness of Metro Mapping in selected care paths of three different cancers and countries, making the research process transparent and reproducible. Trial registration: The pre-test–post-test study has been registered in the clinical.gov trial registry (record number: 8423, identifier: NCT06685562, registration date: 12 November 2024).
- Open Access
- 16 October 2026
- Published by Oxford University Press (OUP) in Skin Health and Disease
Effectiveness of the DEDIKASI-app on awareness of skin diseases in Indonesia: a cluster-randomized controlled trial
Background: Skin diseases are a major public health issue, particularly in low- and middle-income countries, where community awareness about early detection is limited. Objectives: To evaluate the effectiveness of the DEDIKASI-app, a mobile health application, in improving public awareness of skin diseases in Indonesia. Methods: A cluster-randomized controlled trial was carried out in Pamekasan District, East Java, Indonesia, with 630 participants from 21 community health centre areas, randomized to the intervention or control group. We administered a validated questionnaire pre- and postintervention to assess knowledge, prevention practices and health-seeking behaviour related to common skin diseases, including leprosy. The intervention group received access to the DEDIKASI-app, which included features for symptom reporting, health education and digital communication with healthcare workers. Differences between pre- and postintervention scores were analysed using nonparametric tests due to non-normal data distribution. The Wilcoxon signed-rank test assessed within-group changes, and Mann–Whitney U tests compared delta changes between groups. P-values < 0.01 were considered to be statistically significant. Results: The intervention group showed a significant improvement in total awareness scores [mean (SD) delta 24.70 (17.19)] compared with the control group [3.68 (19.07); P < 0.01]. Substantial gains were observed in disease knowledge and health-seeking behaviour domains. In total, 18.3% (n = 55/300) of participants in the intervention group submitted symptom reports via the app and several serious conditions, such as suspected leprosy and skin cancer, were identified, indicating the app’s utility in early detection. Conclusions: The DEDIKASI-app enhanced public awareness and health-seeking behaviour related to skin diseases, and effectively bridged gaps in knowledge and access, addressing barriers such as stigma, lack of trained personnel and limited resources. It holds promise for broader implementation in resource-limited settings, and scaling up could further amplify its benefits, contributing to the global effort in managing skin diseases and reducing their burden.
- 16 October 2026
- Published by Oxford University Press (OUP) in Skin Health and Disease
Open AccessEffectiveness of the DEDIKASI-app on awareness of skin diseases in Indonesia: a cluster-randomized controlled trial
Background: Skin diseases are a major public health issue, particularly in low- and middle-income countries, where community awareness about early detection is limited. Objectives: To evaluate the effectiveness of the DEDIKASI-app, a mobile health application, in improving public awareness of skin diseases in Indonesia. Methods: A cluster-randomized controlled trial was carried out in Pamekasan District, East Java, Indonesia, with 630 participants from 21 community health centre areas, randomized to the intervention or control group. We administered a validated questionnaire pre- and postintervention to assess knowledge, prevention practices and health-seeking behaviour related to common skin diseases, including leprosy. The intervention group received access to the DEDIKASI-app, which included features for symptom reporting, health education and digital communication with healthcare workers. Differences between pre- and postintervention scores were analysed using nonparametric tests due to non-normal data distribution. The Wilcoxon signed-rank test assessed within-group changes, and Mann–Whitney U tests compared delta changes between groups. P-values < 0.01 were considered to be statistically significant. Results: The intervention group showed a significant improvement in total awareness scores [mean (SD) delta 24.70 (17.19)] compared with the control group [3.68 (19.07); P < 0.01]. Substantial gains were observed in disease knowledge and health-seeking behaviour domains. In total, 18.3% (n = 55/300) of participants in the intervention group submitted symptom reports via the app and several serious conditions, such as suspected leprosy and skin cancer, were identified, indicating the app’s utility in early detection. Conclusions: The DEDIKASI-app enhanced public awareness and health-seeking behaviour related to skin diseases, and effectively bridged gaps in knowledge and access, addressing barriers such as stigma, lack of trained personnel and limited resources. It holds promise for broader implementation in resource-limited settings, and scaling up could further amplify its benefits, contributing to the global effort in managing skin diseases and reducing their burden.
- Open Access
- 1 September 2026
- Published by Elsevier in SSRN Electronic Journal
Understanding cancer patients’ preferred and experienced modes of information provision and decisional roles: a cross-sectional questionnaire study in seven European countries
Objectives: Shared Decision Making (SDM) in oncology relies on clear information provision and concordance between patients’ preferred and experienced decisional roles. This study examined preferred and experienced modes of information provision and decisional roles, and assessed whether these varied patients’ by country, cancer type, and sociodemographic characteristics.Methods: A cross-sectional digital survey was conducted among 2,508 respondents with cancer across seven European countries. Modes of information provision were assessed, and decisional roles were measured using the Control Preferences Scale (active, collaborative, passive role). Analyses included chi-square tests, weighted kappa, and multinomial logistic regression.Results: Overall, 69% of respondents reported having been informed about treatment options, ranging from 36% in Sweden to 95% in the UK. Face-to-face information was preferred by 95% but experienced by 68%. Decision Support Tools were preferred by 33% but experienced by 4%. Preferred decisional roles were collaborative (51%), followed by active (26%) and passive (24%), whereas experienced roles were passive (46%), collaborative (31%) and active (23%). Concordance between preferred and experienced roles was 63%. Regression analyses showed associations between decisional roles and country, cancer type, and gender. Respondents from Germany and the UK were more likely to prefer and experience active roles, whereas respondents from Spain and Sweden were more likely to experience passive roles. Female respondents were less likely to prefer an active role. Conclusions: This study highlights gaps between preferences and experiences in European cancer care. Decision-making was generally experienced as more clinician-led than preferred. Improved integration of Decision Support Tools and better alignment of care with patient preferences may enhance SDM.
- 1 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUnderstanding cancer patients’ preferred and experienced modes of information provision and decisional roles: a cross-sectional questionnaire study in seven European countries
Objectives: Shared Decision Making (SDM) in oncology relies on clear information provision and concordance between patients’ preferred and experienced decisional roles. This study examined preferred and experienced modes of information provision and decisional roles, and assessed whether these varied patients’ by country, cancer type, and sociodemographic characteristics.Methods: A cross-sectional digital survey was conducted among 2,508 respondents with cancer across seven European countries. Modes of information provision were assessed, and decisional roles were measured using the Control Preferences Scale (active, collaborative, passive role). Analyses included chi-square tests, weighted kappa, and multinomial logistic regression.Results: Overall, 69% of respondents reported having been informed about treatment options, ranging from 36% in Sweden to 95% in the UK. Face-to-face information was preferred by 95% but experienced by 68%. Decision Support Tools were preferred by 33% but experienced by 4%. Preferred decisional roles were collaborative (51%), followed by active (26%) and passive (24%), whereas experienced roles were passive (46%), collaborative (31%) and active (23%). Concordance between preferred and experienced roles was 63%. Regression analyses showed associations between decisional roles and country, cancer type, and gender. Respondents from Germany and the UK were more likely to prefer and experience active roles, whereas respondents from Spain and Sweden were more likely to experience passive roles. Female respondents were less likely to prefer an active role. Conclusions: This study highlights gaps between preferences and experiences in European cancer care. Decision-making was generally experienced as more clinician-led than preferred. Improved integration of Decision Support Tools and better alignment of care with patient preferences may enhance SDM.
- Open Access
- 8 August 2026
- Published by Elsevier in Translational Oncology
- Vol. 72
Prediction models for adverse events from prostate cancer curative radiotherapy: a systematic review of methodological quality
- 8 August 2026
- Published by Elsevier in Translational Oncology
- Vol. 72
Open AccessPrediction models for adverse events from prostate cancer curative radiotherapy: a systematic review of methodological quality
- Open Access
- 13 January 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (3) , 369-380
End-of-life preparedness and emotional suffering in patients and caregivers: Findings from an international cohort study spanning the period before and after death
Background: Preparing for the end of life is believed to help mitigate emotional suffering for both patients and their caregivers. However, empirical evidence on the emotional benefits of feeling prepared for death remains limited. Aim: This study uses data from the international iLIVE project to examine how perceived end-of-life preparedness is associated with emotional suffering among patients and their caregivers before and after death. Design: Data from a prospective cohort study from the iLIVE project (2020–2023) were analyzed. Participants were surveyed at baseline, 1-month follow-up, and where possible after the patient’s death. The association between end-of-life preparedness (ICECAP-SCM/CPM) and emotional suffering (ICECAP-SCM/CPM & HGRC) was examined using OLS regression models, adjusting for socio-demographic and health-related covariates. Setting/participant: Data came from 1041 patients and 496 caregivers across 11 countries, enrolled in the iLIVE project. Results: Feeling fully prepared for the end of life was significantly associated with lower levels of emotional suffering for both patients and caregivers. Among patients, preparedness was linked to reduced emotional suffering at baseline and follow-up. For caregivers, these associations were even more pronounced at baseline, follow-up, and after the patient’s death. Conclusions: Perceived preparedness for the end of life was associated with lower emotional suffering for patients approaching death and their caregivers, both during the illness and after bereavement. These findings suggest that encouraging end-of-life planning may support emotional well-being across the final phase of life and beyond.
- 13 January 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (3) , 369-380
Open AccessEnd-of-life preparedness and emotional suffering in patients and caregivers: Findings from an international cohort study spanning the period before and after death
Background: Preparing for the end of life is believed to help mitigate emotional suffering for both patients and their caregivers. However, empirical evidence on the emotional benefits of feeling prepared for death remains limited. Aim: This study uses data from the international iLIVE project to examine how perceived end-of-life preparedness is associated with emotional suffering among patients and their caregivers before and after death. Design: Data from a prospective cohort study from the iLIVE project (2020–2023) were analyzed. Participants were surveyed at baseline, 1-month follow-up, and where possible after the patient’s death. The association between end-of-life preparedness (ICECAP-SCM/CPM) and emotional suffering (ICECAP-SCM/CPM & HGRC) was examined using OLS regression models, adjusting for socio-demographic and health-related covariates. Setting/participant: Data came from 1041 patients and 496 caregivers across 11 countries, enrolled in the iLIVE project. Results: Feeling fully prepared for the end of life was significantly associated with lower levels of emotional suffering for both patients and caregivers. Among patients, preparedness was linked to reduced emotional suffering at baseline and follow-up. For caregivers, these associations were even more pronounced at baseline, follow-up, and after the patient’s death. Conclusions: Perceived preparedness for the end of life was associated with lower emotional suffering for patients approaching death and their caregivers, both during the illness and after bereavement. These findings suggest that encouraging end-of-life planning may support emotional well-being across the final phase of life and beyond.
- Open Access
- 9 December 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 144, 109446
Participating in decision-making at the end of life: The self-reported ability of people with cancer across 11 countries
- 9 December 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 144, 109446
Open AccessParticipating in decision-making at the end of life: The self-reported ability of people with cancer across 11 countries
- Open Access
- 1 December 2025
- Published by Lepra in Leprosy Review
- Vol. 96 (4)
Mobile-phone application for the early detection of common skin diseases in Indonesia (DEDIKASI-App): development and acceptability testing
Background Skin diseases are highly prevalent, especially in low-income communities, leading to anxiety, depression, and stigma. This study developed and assessed the acceptability of the DEDIKASI app, a two-way mHealth application designed to enhance awareness and support early detection of common skin diseases, including leprosy. Methods The app was developed through design thinking, incorporating inspiration, ideation, and implementation. A cross-sectional survey in Pamekasan District, Indonesia, piloted the app among 50 community members and 21 healthcare workers (HCWs). Participants completed self-administered questionnaires based on the Technology Acceptance Model (TAM), assessing perceived usefulness, perceived ease of use, attitude towards use, and behavioural intention to use. Four supplementary constructs – security and privacy, technology usability, quality of information, and perceived benefit – were examined. The total number of items was 31 and 28 for community members and HCWs, respectively. Response options on 5-point Likert scales ranged from 'very much agree' to 'undecided' to 'very much disagree'. Data were analysed using descriptive statistics. Results The DEDIKASI app demonstrated high acceptability, with 90% of community members and 86% of HCWs intending to use it. Some community members expressed concerns regarding ease of use (14% undecided), security and privacy (12% undecided), and information quality (4% undecided). HCWs reported no negative responses, though some remained undecided about security and usability. Conclusions The DEDIKASI app has strong potential for raising awareness and facilitating early detection of skin diseases, contributing to improved public health outcomes. Enhancements in usability, security, and information quality may further increase user satisfaction and acceptance.
- 1 December 2025
- Published by Lepra in Leprosy Review
- Vol. 96 (4)
Open AccessMobile-phone application for the early detection of common skin diseases in Indonesia (DEDIKASI-App): development and acceptability testing
Background Skin diseases are highly prevalent, especially in low-income communities, leading to anxiety, depression, and stigma. This study developed and assessed the acceptability of the DEDIKASI app, a two-way mHealth application designed to enhance awareness and support early detection of common skin diseases, including leprosy. Methods The app was developed through design thinking, incorporating inspiration, ideation, and implementation. A cross-sectional survey in Pamekasan District, Indonesia, piloted the app among 50 community members and 21 healthcare workers (HCWs). Participants completed self-administered questionnaires based on the Technology Acceptance Model (TAM), assessing perceived usefulness, perceived ease of use, attitude towards use, and behavioural intention to use. Four supplementary constructs – security and privacy, technology usability, quality of information, and perceived benefit – were examined. The total number of items was 31 and 28 for community members and HCWs, respectively. Response options on 5-point Likert scales ranged from 'very much agree' to 'undecided' to 'very much disagree'. Data were analysed using descriptive statistics. Results The DEDIKASI app demonstrated high acceptability, with 90% of community members and 86% of HCWs intending to use it. Some community members expressed concerns regarding ease of use (14% undecided), security and privacy (12% undecided), and information quality (4% undecided). HCWs reported no negative responses, though some remained undecided about security and usability. Conclusions The DEDIKASI app has strong potential for raising awareness and facilitating early detection of skin diseases, contributing to improved public health outcomes. Enhancements in usability, security, and information quality may further increase user satisfaction and acceptance.
- Open Access
- 30 October 2025
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (2) , 280-289
Beyond the Pandemic: End-of-Life Care Lessons From Latin America to Inform Future Health Emergencies
- 30 October 2025
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (2) , 280-289
Open AccessBeyond the Pandemic: End-of-Life Care Lessons From Latin America to Inform Future Health Emergencies
- Open Access
- 22 September 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 142, 109355
Do patients who underestimate their health decline rely more on doctors? Insights from patients in their last six months of life
- 22 September 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 142, 109355
Open AccessDo patients who underestimate their health decline rely more on doctors? Insights from patients in their last six months of life
- Open Access
- 8 September 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e64057
Increasing Awareness and Early Detection of Common Skin Diseases in Indonesia Through an mHealth App: Protocol for an Awareness and Acceptability Study and Randomized Controlled Trial
Background: Various media are used to enhance public understanding about diseases. While mobile health apps are widely used, there is little proof for using such apps to raise awareness of skin diseases. Objective: We intend to develop an app, called DEDIKASI-app, to raise awareness of skin diseases, including leprosy. The study will explore baseline awareness, assess the app’s acceptance by community members and health care workers, and evaluate its effectiveness in enhancing awareness about skin diseases. Methods: The study will be conducted in four phases: (1) development of DEDIKASI-app, (2) questionnaire development for an awareness study, (3) acceptability testing, and (4) effect measurement of DEDIKASI-app. We will adopt design thinking methodology to develop the app, involving systematic reviews, expert consultations, focus group discussions, and validation of the questionnaire on skin disease awareness. We will recruit 50 members of the community for the awareness and acceptability study and 1 health care worker per community health center to assess their perception of the app. A pilot study will assess the acceptability of DEDIKASI-app among community members and health care workers based on various constructs, with responses categorized as positive, negative, or undecided. The validity and reliability of a newly developed questionnaire on skin disease awareness will be tested, with validity results analyzed qualitatively and reliability measured using Cronbach α. The effectiveness of DEDIKASI-app in improving community awareness will be evaluated through a randomized controlled trial, using total scores, means, and SDs for control and intervention groups. Statistical significance of awareness level changes will be determined by delta change (P value), with P<.01 considered significant. Results: This study received ethical approval from the Ethics Review Board of the Faculty of Public Health, Universitas Airlangga (160/EA/KEPK/2023) and was registered in the Indonesia Clinical Research Registry (INA-O8EX278). Funding for the field research was secured in the period of May 2022-December 2024 from NLR Indonesia and Erasmus University Medical Center. As of manuscript submission, phase 1 (app development) and phase 2 (questionnaire development) have been completed. Data collection for the randomized controlled trial has just finished and data analysis is ongoing, with publication of the study results expected in late 2025. Conclusions: Innovative approaches are required to enhance awareness in the community. This study will introduce new tools and insights to address the limited knowledge about detecting skin problems. Trial Registration: INA-CRR Indonesia Clinical Research Registry INA-O8EX278; https://tinyurl.com/ms3k5yvn International Registered Report Identifier (IRRID): DERR1-10.2196/64057
- 8 September 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e64057
Open AccessIncreasing Awareness and Early Detection of Common Skin Diseases in Indonesia Through an mHealth App: Protocol for an Awareness and Acceptability Study and Randomized Controlled Trial
Background: Various media are used to enhance public understanding about diseases. While mobile health apps are widely used, there is little proof for using such apps to raise awareness of skin diseases. Objective: We intend to develop an app, called DEDIKASI-app, to raise awareness of skin diseases, including leprosy. The study will explore baseline awareness, assess the app’s acceptance by community members and health care workers, and evaluate its effectiveness in enhancing awareness about skin diseases. Methods: The study will be conducted in four phases: (1) development of DEDIKASI-app, (2) questionnaire development for an awareness study, (3) acceptability testing, and (4) effect measurement of DEDIKASI-app. We will adopt design thinking methodology to develop the app, involving systematic reviews, expert consultations, focus group discussions, and validation of the questionnaire on skin disease awareness. We will recruit 50 members of the community for the awareness and acceptability study and 1 health care worker per community health center to assess their perception of the app. A pilot study will assess the acceptability of DEDIKASI-app among community members and health care workers based on various constructs, with responses categorized as positive, negative, or undecided. The validity and reliability of a newly developed questionnaire on skin disease awareness will be tested, with validity results analyzed qualitatively and reliability measured using Cronbach α. The effectiveness of DEDIKASI-app in improving community awareness will be evaluated through a randomized controlled trial, using total scores, means, and SDs for control and intervention groups. Statistical significance of awareness level changes will be determined by delta change (P value), with P<.01 considered significant. Results: This study received ethical approval from the Ethics Review Board of the Faculty of Public Health, Universitas Airlangga (160/EA/KEPK/2023) and was registered in the Indonesia Clinical Research Registry (INA-O8EX278). Funding for the field research was secured in the period of May 2022-December 2024 from NLR Indonesia and Erasmus University Medical Center. As of manuscript submission, phase 1 (app development) and phase 2 (questionnaire development) have been completed. Data collection for the randomized controlled trial has just finished and data analysis is ongoing, with publication of the study results expected in late 2025. Conclusions: Innovative approaches are required to enhance awareness in the community. This study will introduce new tools and insights to address the limited knowledge about detecting skin problems. Trial Registration: INA-CRR Indonesia Clinical Research Registry INA-O8EX278; https://tinyurl.com/ms3k5yvn International Registered Report Identifier (IRRID): DERR1-10.2196/64057